Covered recipient · General Payments record
TINA C ZECCA
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$51,329.86
216 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,425.00 | 14 |
| Honoraria | $20,915.63 | 16 |
| Food and Beverage | $3,746.37 | 175 |
| Travel and Lodging | $2,135.36 | 9 |
| Education | $107.50 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Aimmune Therapeutics, Inc. | $21,161.47 | 32 |
| OptiNose US, Inc. | $11,783.27 | 26 |
| AstraZeneca Pharmaceuticals LP | $7,727.04 | 17 |
| Grifols USA, LLC | $4,929.98 | 20 |
| PFIZER INC. | $3,976.56 | 11 |
| GlaxoSmithKline, LLC. | $459.55 | 26 |
| Regeneron Healthcare Solutions, Inc. | $208.54 | 11 |
| ALK-Abello, Inc | $135.70 | 6 |
| Teva Pharmaceuticals USA, Inc. | $105.78 | 7 |
| Amgen Inc. | $93.71 | 7 |
| Incyte Corporation | $75.14 | 5 |
| Hikma Pharmaceuticals USA | $56.09 | 4 |
| kaleo, Inc. | $54.52 | 4 |
| Bio Products Laboratory USA, Inc. | $53.42 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $53.25 | 4 |
| Novartis Pharmaceuticals Corporation | $52.97 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $42.73 | 3 |
| Blueprint Medicines Corporation | $42.72 | 1 |
| LEO Pharma Inc. | $42.70 | 3 |
| CSL Behring | $40.00 | 3 |
| Phadia US Inc. | $39.55 | 3 |
| BioCryst US Sales Co., LLC | $37.69 | 3 |
| Genentech USA, Inc. | $28.20 | 2 |
| GENZYME CORPORATION | $27.38 | 2 |
| AYTU BioPharma, Inc. | $25.63 | 2 |
| Covis Pharma GmBH | $25.48 | 2 |
| ADMA BioManufacturing LLC | $24.12 | 3 |
| Octapharma USA, Inc. | $14.36 | 1 |
| Insmed, Inc. | $12.31 | 1 |
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TINA C ZECCA
NPI 1790753630 · CMS profile ID 307552
Allopathic & Osteopathic Physicians / Allergy & Immunology
LITTLE SILVER, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790753630?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TINA C ZECCA, NPI 1790753630, CMS profile ID 307552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790753630?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). TINA C ZECCA, NPI 1790753630, CMS profile ID 307552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790753630?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- TINA C ZECCA, NPI 1790753630, CMS profile ID 307552, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1790753630?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
216 matching records · $51,329.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–216 of 216.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $3.40 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927487285 | CMS |
| OptiNose US, Inc. | $920.00 | 02/14/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 928129693 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.83 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915121029 | CMS |
| CSL Behring | $14.36 | 02/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940895151 | CMS |
| GlaxoSmithKline, LLC. | $12.58 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945199767 | CMS |
| PFIZER INC. | $10.50 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949082275 | CMS |
| Amgen Inc. | $12.93 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939444489 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,200.00 | 01/25/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915390727 | CMS |
| GlaxoSmithKline, LLC. | $11.05 | 01/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945199799 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.12 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956012293 | CMS |
| Insmed, Inc. | $12.31 | 01/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 906414069 | CMS |
| Grifols USA, LLC | $12.80 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918657621 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.72 | 01/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915136321 | CMS |
| AstraZeneca Pharmaceuticals LP | $244.39 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915732321 | CMS |
| Bio Products Laboratory USA, Inc. | $13.47 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937422301 | CMS |
| ADMA BioManufacturing LLC | $7.68 | 01/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933559215 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $38,245.10 | 5 |
| PY2024 | Principal investigator | $13,943.27 | 2 |
| PY2023 | Principal investigator | $22,670.86 | 3 |
| PY2022 | Principal investigator | $20,342.81 | 1 |
| PY2020 | Principal investigator | $30,420.24 | 8 |
| PY2019 | Principal investigator | $19,180.40 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
5 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22.58 | 11/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190310018 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $146.78 | 10/08/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF MONMOUTH COUNTY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190311525 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $40.50 | 08/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF MONMOUTH COUNTY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190312009 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $112.90 | 01/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190310020 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,922.34 | 01/01/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190306983 |